Regulus Therapeutics (RGLS) Given Hold Rating at Wedbush

Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “hold” rating reiterated by equities researchers at Wedbush in a report released on Thursday, AnalystRatings.com reports. They presently have a $1.00 price target on the biopharmaceutical company’s stock. Wedbush’s price objective points to a potential downside of 16.67% from the company’s previous close. Wedbush also issued estimates for Regulus Therapeutics’ Q2 2019 earnings at ($0.19) EPS, Q3 2019 earnings at ($0.27) EPS, Q4 2019 earnings at ($0.25) EPS, FY2019 earnings at ($1.41) EPS, Q1 2020 earnings at ($0.26) EPS, Q2 2020 earnings at ($0.27) EPS, Q3 2020 earnings at ($0.28) EPS, Q4 2020 earnings at ($0.29) EPS and FY2020 earnings at ($1.09) EPS.

Other equities analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Friday, March 29th. Wells Fargo & Co dropped their price target on shares of Regulus Therapeutics from $6.00 to $1.50 and set a “market perform” rating on the stock in a research note on Tuesday, March 19th. Finally, ValuEngine lowered shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. Regulus Therapeutics presently has an average rating of “Hold” and an average price target of $1.06.

Shares of RGLS stock traded down $0.13 during trading hours on Thursday, reaching $1.20. 2,671 shares of the stock were exchanged, compared to its average volume of 255,743. Regulus Therapeutics has a 12-month low of $0.80 and a 12-month high of $9.48. The firm has a market capitalization of $13.27 million, a price-to-earnings ratio of -0.21 and a beta of 2.26.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.15) by $0.84. Regulus Therapeutics had a negative net margin of 526.10% and a negative return on equity of 186,717.70%. The firm had revenue of $6.78 million for the quarter, compared to analyst estimates of $0.02 million. As a group, sell-side analysts forecast that Regulus Therapeutics will post -2.39 earnings per share for the current fiscal year.

In other Regulus Therapeutics news, Director Pascale Witz bought 29,630 shares of the stock in a transaction dated Tuesday, May 7th. The shares were acquired at an average cost of $1.08 per share, for a total transaction of $32,000.40. Following the completion of the transaction, the director now owns 37,849 shares in the company, valued at approximately $40,876.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Peter J. Barris bought 1,136,704 shares of the stock in a transaction dated Tuesday, May 7th. The shares were acquired at an average price of $1.08 per share, for a total transaction of $1,227,640.32. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 1,199,528 shares of company stock worth $1,295,490 and sold 11,805 shares worth $11,569. Corporate insiders own 5.40% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in RGLS. Jane Street Group LLC bought a new stake in Regulus Therapeutics during the first quarter worth $64,000. Renaissance Technologies LLC lifted its stake in Regulus Therapeutics by 72.2% during the first quarter. Renaissance Technologies LLC now owns 275,693 shares of the biopharmaceutical company’s stock worth $281,000 after purchasing an additional 115,625 shares during the last quarter. Wedbush Securities Inc. lifted its stake in Regulus Therapeutics by 32.8% during the first quarter. Wedbush Securities Inc. now owns 43,489 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 10,751 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in Regulus Therapeutics during the first quarter worth $68,000. Institutional investors and hedge funds own 25.17% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Recommended Story: Diversification Important in Investing

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit